AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04900272 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VIPA and companion booklet
Description: Participants will be asked to use the VIPA and accompanying second iteration of the instructional booklet focused on social-isolation. These participants will be surveyed over the phone for 16 weeks (baseline, 2 weeks, 4 weeks, 8 weeks, and 16 weeks) with outcomes measured at each time point.
Study NCT00430118 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT04159064 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Thromboelastometry, Impedance Aggregometry
Description: Study of coagulation changes after cardiac surgery on CPB using Minimal Extracorporeal Circulation
Study NCT00397579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DT388IL3
Description: Intravenously via a 3 cc plastic syringe as a 15 minute bolus infusion daily for five days.
Study NCT01422109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH14659
Description: YH14659 capsule by oral
Study NCT01422109 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel & aspirin
Description: clopidogrel tablet(75mg) + aspirin capsules(100mg) by oral
Study NCT01137786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non ionic contrast media comparator
Description: One time administration for PCI
Study NCT04125576 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: magnetic resonance imaging(MRI)
Description: magnetic resonance imaging(MRI) will be used to evaluate cerebral blood volume(CBV) of pain network
Study NCT03798262 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gluten
Description: Tereos
Study NCT03798262 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Whey protein from Nestlé Healthy Science
Study NCT01137786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non ionic contrast media comparator
Description: one time administration for PCI
Study NCT04640896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trigger point injection with bupivacaine
Description: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
Study NCT04640896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trigger point injection with normal saline
Description: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.
Study NCT04640896 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Lidocaine skin wheal
Description: Patients in the control group will receive a small skin wheal of lidocaine. This will keep the patient blinded to the study group they are in since all patients will receive an injection.~However, this skin wheal is not considered a trigger point injection.
Study NCT02237664 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous paravertebral analgesia (C-PVB)
Description: Patients will receive continuous paravertebral infusion of bupivacaine 0.2% and fentanyl 2 μg mL-1 at rate of 8 mL h-1
Study NCT02237664 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient-controlled paravertebral analgesia (PC-PVB)
Description: Patients will receive background continuous paravertebral infusion of bupivacaine 0.2% and fentanyl 2 μg mL-1 at rate of 8 mL h-1 with patient demand bolus dose of 3 mL and lockout time of 15 min with a 20 mL h-1 maximum dose, irrespective of their age
Study NCT00430118 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study NCT00851903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Subcutaneous injection. 100 Units/mL solution for injection in a prefilled SoloStar® pen (3 mL).
Study NCT00851903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Oral administration. 100mg film-coated tablets.
Study NCT00851903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Patients continued with metformin as usual oral anti-diabetic treatment.
Study NCT01475890 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 7000IU per day of vitamin D3 for 12 months.
Study NCT01475890 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once a day for 12 months.
Study NCT05551130 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restoration
Description: Restorations completed with these materials.
Study NCT02979314 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Galvanic Vestibular Stimulation
Description: The investigators aim to study the influence of Galvanic Vestibular Stimulation on the brain mechanisms underlying illusory self-motion and its influence on egocentric mental transformation. As a control condition sham stimulation will be applied by the same device within the same participants in different trials. Participants should not note the difference.
Study NCT03132077 — intervention group
Intervention type: PROCEDURE
Intervention: total knee arthroplasty
Description: surgical intervention for end stage of knee osteoarthritis
Study NCT02163070 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey drink,
Description: consumption of 220 milliliters of whey drink three times a week,
Study NCT02163070 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey drink fortified with vitaminE
Description: consumption of 220 milliliters of whey drink fortified with 400 milligrams of vitamin E three times a week,
Study NCT02163070 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin E
Description: consumption of 400 milligrams of vitamin E three times a week,
Study NCT02461017 — intervention group
Intervention type: OTHER
Intervention: Assess for Audible Endotracheal Leak
Description: In supine position, the head will be positioned in neutral position. With fresh gas flow at 2-5L/min, and pop off valve in the anesthesia machine closed and pressure in the inspiratory circuit is slowly increased until an audible leak is heard at the mouth. That pressure will be recorded.
Study NCT02461017 — intervention group
Intervention type: OTHER
Intervention: Assess for Endotracheal Leak with direct visualization under rigid bronchoscope
Description: In the same patient position, a flexible nasal laryngoscope will be inserted and positioned superior to the laryngeal inlet by the surgeon. With fresh gas flow at 2-5L/min, and pop off valve in the anesthesia machine closed, the pressure in the inspiratory circuit will be increased slowly until a leak around the TT will be visualized by inspecting the supraglottic area for bubbles or air movement around the TT. The peak pressure at which leak is observed physically will be recorded. This is the end of the study.
Study NCT02318095 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine/nab-Paclitaxel
Description: Prospective, single arm study ; eligible subjects will recieve 2 cycles of neoadjuvant Gemcitabine/nab-Paclitaxel. All chemotherapy administered to study subjects is standard of care. The chemotherapy combination, gemcitabine/nab-paclitaxel, is considered to be a standard-of-care, non-investigational chemotherapy combination; chemotherapy dosing and treatment schedule will be managed by the treating medical oncologist. Restaging will be completed post chemotherapy.
Study NCT02318095 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation therapy
Description: 5 fractions of hypofractionated IGRT or IMRT at 5Gy per fraction will be delivered before surgery. Restaging will be completed post radiation therapy.
Study NCT02318095 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sugical resection
Description: Surgical resection of the pancreas post radiation therapy
Study NCT02318095 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Adjuvant chemotheapy
Description: Adjuvant chemotherapy may be given after surgery at the clinical discretion of the medical oncologist
Study NCT04561349 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task oriented training
Description: Task oriented training consisted of different functional tasks for lower limbs to improve balance and walk. Each task was given 5 minutes Tasks were progressed according to each child's performance. These progressions included increase of repetitions, speed and switching between the tasks. One hour practice of these tasks was advised for home plan
Study NCT04561349 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation treatment
Description: Conventional rehabilitation treatment includes mat activities and ROM of all limbs, Lower limb strengthening and stretching, walking, cycling.~Each exercise was performed for 5 minutes. One hour practice of above exercises and thermotherapy for the spastic muscles advised for 10 minutes once a day at home was advised.
Study NCT01906749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: 0.5mg once daily orally
Study NCT02474368 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Study NCT01906749 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01895530 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Description: The patients received one oral lyophilized yeast capsule, each of which contains 100 mg (0,5 x 109 cfu/g) of Saccharomyces boulardii (Merck S.A., Biocodex, Beauvais, French), once a day. The treatment started at least seven days before surgery and stopped on the operation day.
Study NCT03290014 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: polysomnography
Description: Monitoring of brain activity and respiratory variables during sleep
Study NCT03290014 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Actigraphy
Description: monitoring daily physical activity for 7 days
Study NCT03290014 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Osler test
Description: Evaluation of subjects´ ability to remain awake
Study NCT03420976 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Novel Supplement Based Therapy
Description: Supplements and Dosage:~Detox Support: Liver-G.I. Detox BID for 30 days GI Support: L-Glutamine Powder 2 scoops QD for 35 days Microbial Balance: MicroDefense 1 capsule QD for 49 days Microbial Balance: A.C. Formula II 2 capsules BID for 49 days Probiotic: Probiotic-5 1 capsule QD for 49 days Digestive Enzymes: Digestive Enzymes Ultra with Betaine HCl As needed up to 6 longer term
Study NCT00686127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidoderm patch
Description: 1 patch was applied topically to the affected site(s) for 12 hours each day.
Study NCT00686127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: 1 patch was applied topically to the affected site(s) for 12 hours each day.
Study NCT04584177 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arm-hand BOOST program
Description: The arm-hand boost program is provided 1 hour/day, 5x/week for 4 weeks, on top of their usual care program. The focus of the boost program is on scapula-setting, core-stability when reaching, movements with 30-60° flexion/abduction in shoulder, fine manipulation and integration in complex ADL tasks. Additionally, patients exercise 1 hour per week using the Armeo Power (Hocoma). Therefore, the additional arm-hand boost program consists of 24 one-hour sessions, provided over four weeks.
Study NCT04584177 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control program
Description: A dose-matched program of strengthening exercises for the lower limbs and general reconditioning
Study NCT02570451 — intervention group
Intervention type: OTHER
Intervention: Patient Survey
Description: This survey will assess patients' perspective about the importance of preoperative cognitive screening, information about living situation, information about who accompanied them to the preoperative visit, and level of perceived stress.
Study NCT02570451 — intervention group
Intervention type: OTHER
Intervention: Mini Cog
Description: The MiniCog is a simple cognitive screening tool that takes just 2-4 min to complete and has little or no education, language, or race bias. This is a well-validated tool to assess mild cognitive impairment.
Study NCT02570451 — intervention group
Intervention type: OTHER
Intervention: Independent Activities of Daily Living Score Sheet
Description: Questionnaire used to measure self-reported functional status for instrumental activities of daily living using standardized scales
Study NCT02570451 — intervention group
Intervention type: OTHER
Intervention: Activities of Daily Living Score Sheet
Description: Questionnaire used to measure self-reported functional status for basic activities of daily living using standardized scores
Study NCT02570451 — intervention group
Intervention type: OTHER
Intervention: Geriatric Depression Scale Short Form
Description: Questionnaire used to measure self-reported mood
Study NCT02570451 — intervention group
Intervention type: OTHER
Intervention: Confusion Assessment Method (CAM)
Description: This well-validated measure of post-operative delirium will be utilized up to 3 days after surgery
Study NCT02570451 — intervention group
Intervention type: OTHER
Intervention: RAND 36-Item Short Form Health Survey
Description: This measure is a generic, coherent, and easily administered health survey used to assess self-reported quality of life
Study NCT02570451 — intervention group
Intervention type: OTHER
Intervention: Grip Strength
Description: Measured using the JAMAR dynamometer
Study NCT04391933 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI 3 tesla
Description: MRI of colon cancer. Sensitivity, specificity, positivity predictive values and negative predictive values are calculated form the histopathological surgical specimen. This will be the endpoint for both CT and MRI.
Study NCT02411552 — intervention group
Intervention type: BEHAVIORAL
Intervention: physical activity
Description: 4 strategies are: (1) increased activity time during physical education class, (2) active recess, (3) opportunities for activity before and after school, and (4) active classroom breaks
Study NCT01832259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib, 800 mg, orally daily for 28 days prior to radical prostatectomy.
Study NCT01832259 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet orally, daily for 28 days prior to radical prostatectomy.
Study NCT01043380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination therapy with Lipitor [Atorvastatin] and Zetia [Ezetimibe]
Description: Zetia 10 mg/dl + Lipitor. The dosage of Lipitor will be titrated up to a maximum of 20 mg/day with a treatment goal of lowering LDL-C below 70 mg/dl.
Study NCT01043380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipitor (Atorvastatin) monotherapy
Description: The dosage will be titrated up to a maximum of 20 mg/day, which is the highest approved regimen by the Ministry of Health, Labor and Welfare of Japan, with a treatment goal of lowering LDL-C below 70 mg/dl.
Study NCT04271462 — intervention group
Intervention type: OTHER
Intervention: Comparing two CO2 absorbers in the ventilator circuit
Description: General anaesthesia will be induced with a standardised regimen (propofol 0.8-2.5 mg·kg-1, sufentanil 0.2 - 0.5 µg·kg-1 and rocuronium 0.5 - 1 mg·kg-1). After tracheal intubation, anaesthesia will be maintained with sevoflurane targeted at 1 MAC end tidal concentration (corrected for age using the formula by Mapleson) in 40% O2. Different ventilator settings will be compared for 30 minutes (in randomised order):~I. Sodalime, FGF 2.0 L min-1. II. Amsorb Plus®, FGF 2.0 L min-1. III. Soda lime, FGF, 0.5 L min-1. IV. Amsorb Plus®, FGF 0.5 L min-1. FGF=fresh gas flow.
Study NCT01091961 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative ACEi/ARB management
Description: Patients will either hold their chronic ACEi/ARB medication for at least 24 hours prior to surgery, or continue to take the ACEi/ARB medication up to and including the day of surgery
Study NCT02247869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dose dense ABVD
Description: dose dense ABVD will be administered intravenously on day 1 and 8 every 21 days Chemotherapy regimen~* Doxorubicin 25 mg/m2 i.v. day 1 and 8~* Bleomycin 10 mg/m2 i.v. day 1 and 8~* Vinblastine 6 mg/m2 i.v. day 1 and 8~* Dacarbazine 375 mg/m2 i.v. day 1 and 8~Granulocyte colony-stimulating factor (G-CSF): days 9 to 14
Study NCT03624738 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procedure
Description: Patients with redo cardiac surgery 1: femoral artery-femoral vein cardiopulmonary bypass (CPB) in order to achieve cardiac decompression prior to sternotomy.~Patients with redo cardiac surgery 2: only conventional aortobicaval cannulation will be used
Study NCT02418130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid, taurine, ginsenoside, thiamine, inositol
Study NCT02418130 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03539432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 MG
Description: Gemfibrozil capsules (600 mg) taken twice per day
Study NCT03539432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Microcrystalline cellulose powder packaged in capsules identical to the experimental medication
Study NCT01381094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-6548
Description: oral dose administered once daily for 42 days
Study NCT01381094 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral Placebo administered once daily for 42 days
Study NCT03934645 — intervention group
Intervention type: OTHER
Intervention: Delirium prediction model for ICU patients, version 1
Description: The pre-deliric model version 1 for intensive care patients consists of ten risk factors that are readily available within 24 hours after intensive care admission and has a high predictive value. The model allows for early prediction of delirium and initiation of preventive measures. Data of the patient in the first 24 hours of admission to the intensive care unit are collected and the delirium prediction score is found.
Study NCT03934645 — intervention group
Intervention type: OTHER
Intervention: Delirium prediction model for ICU patients, version 2
Description: The pre-deliric model version 2 for intensive care patients consists of ten risk factors that are readily available within 24 hours after intensive care admission. Data of the patient in the first 24 hours of admission to the intensive care unit are collected and the delirium prediction score is found. The model allows for early prediction of delirium and initiation of preventive measures.
Study NCT03934645 — intervention group
Intervention type: OTHER
Intervention: Early prediction model for delirium in ICU patients
Description: The e-pre-deliric model enables the clinician to identify those patients likely to develop delirium following ICU admission using only nine predictors. In the e-pre-deliric model, delirium prediction score is determined by inputting the data of the patient in admission to the intensive care unit.
Study NCT01062477 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP//PRP-T Combined Vaccine
Description: 0.5 mL, Intramuscular
Study NCT02474368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT02474368 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Study NCT00646932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paricalcitol
Description: paricalcitol 0.04 mcg/kg three times a week
Study NCT00646932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paricalcitol
Description: paricalcitol 0.08 mcg/kg three times a week
Study NCT00646932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paricalcitol
Description: paricalcitol 0.16 mcg/kg three times a week
Study NCT00646932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paricalcitol
Description: paricalcitol 0.24 mcg/kg three times a week
Study NCT01062477 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP Combined Vaccine and PRP-Tetanus Conjugate Vaccine
Description: 0.5 mL, Intramuscular (each vaccine)